# Prevention of Recurrent Hepatitis B After Liver Transplantation

> **NCT00059267** · — · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 317 (actual)

## Conditions studied

- Hepatitis B
- Cirrhosis
- Acute Liver Failure
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** HBIG, Epivir, Hepsera

## Key facts

- **NCT ID:** NCT00059267
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00059267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00059267, "Prevention of Recurrent Hepatitis B After Liver Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00059267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*